A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

Main Who May Qualify: - diagnosed by tissue sample (biopsy-confirmed) Hepatocellular carcinoma (HCC) - Subjects with HCC who have received at least 2 standard systemic therapies - HLA-A \*02 - BCLC stage B or C - Child-pugh score ≤ 7 - Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA must be 2 × 1000 IU/ml - Have at least one measurable leasion at baseline as per mRECIST and RECIST v1.1 criteria - Life expectancy of 3 months or greater - Ability to provide willing to sign a consent form form - Ability to comply with all the study procedures Main Who Should NOT Join This Trial: - Subjects with history of another primary cancer - Untreated or active central nervous system (CNS) or leptomeningeal metastasis, or history of hepatic encephalopathy, or other clinically significant CNS diseases - autoimmune conditions (where your immune system attacks your own body)s requiring immunosuppressive therapy (except topical medication) or subjects with significant persistent immune rejection - Known history of neurological or mental disorder, including epilepsy or dementia - Known history of positive results for human weakened immune system virus (HIV) 1 or 2 or known acquired weakened immune system syndrome (AIDS) - Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy, CAR T/TCR T cell therapy - Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine) - Any subjects who cannot be evaluated by either triphasic liver CT or triphasic MRI because of allergy or other contraindication to both CT and MRI contrast agents - Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation Always talk to your doctor about whether this trial is right for you.